Identification and characterization of human cytochrome P450 isoforms interacting with pimozide

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 2, 1998, Pages 428-437

  Desta, Zeruesenay ^a   Kerbusch, Thomas ^a   Soukhova, Nadia ^a   Richard, Emily ^a   Ko, Jae Wook ^a   Flockhart, David A ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; CYTOCHROME P450 ISOENZYME; DEXTRORPHAN; DRUG METABOLITE; FURAFYLLINE; KETOCONAZOLE; LEVALLORPHAN; PIMOZIDE; RECOMBINANT ENZYME; TROLEANDOMYCIN;

ARTICLE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME MECHANISM; ENZYME POLYMORPHISM; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0031808548     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Ahmed I, Dagincourt PG, Miller LG and Shader RI (1993) Possible interaction between, fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 38:62-83.
2. Antzelevitch C, Zhuo-Quian S, Zi-Qing Z and Gan-Xin Y (1996) Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsades de pointes. J Am Coll Cardiol 28:1836-1848.
3. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9, Xenobiotica 25:261-270.
4. Balian JD, Soukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, Woosley RL and Flockhart DA (1995) The hydroxylation of omeprazole correlates with S-mephenytnin metabnlism: A population study. Clin Pharmacol Ther 57:662-669.
5. Baro F, Brugnums J and Heykants J (1972) Assorbimento, metabolismo ed excrezione della pimozide nella uomo. Clin Ter 63:239-249.
6. Bertilsson L (1995) Geographical/inter-racial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450 2D6 and 2C19. Clin Pharmacokinet 29:192-209.
7. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
8. Bourriè M, Meunier V, Berger Y and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for investigation of metabolic reactions catalyzed by human liver microBomes. J Pharmacol Exp Ther 277:321-332.
9. Broly F, Libersa C, Lhermitte M, Bechtel P and Dupuis B (1989) Effect of quinidine on the dextromethorphan O-deniethylase activity of microaomal fractions from human liver. Br J Clin Pharmacol 28:29-36.
10. Brosen K (1995) Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet 29: suppl. 1, 20-25.
11. Ching MS, Blake CL, Ghabrial H, Ellis SW, Lennard MS, Tucker GT and Smallwood RA (1995) Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochem Pharmacol 50:833-837.
12. Cohen DJ, Riddle MA and Leckman JF (1992) Pharmacotherapy of Tourette's syndrome and associated disorders. Pediatr Psychopharmacol 15:109-128.
13. Colvin CL and Tankanow RM (1985) Pimozide: Use in Tourette's syndrome. Drug Intell Clin Pharm 19:421-424.
14. Ekins S, VandenBranden M, Ring BJ and Wrighton SA (1997) Examination of purported probes of human CYP2B6, Pharmacogenetics 7:165-171.
15. Flockhart DA, Richard E, Woosley RL, Pearle PL and Drici M-D (1996) Metabolic interaction between clarithromycin and pimozide may result in cardiac toxicity. Clin Pharmacol Ther 59:189A.
16. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E and Nordlie MA (1987) EKG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 144:673-675.
17. Gillum JG, Israel DS and Polk RE (1993) pharmacokinetic interaction with antimicrobial agents. Clin Pharmacokinet 25:450-482.
18. Gorski JC, Jones DR, Wrighton SA and Hall SD (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily, Biochem Pharmacol 48:173-182.
19. Guengerich FP, Kim D-H and Iwasaki H (1991) Role of human cytochrome P450IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
20. Halliday RC, Jones BC, Smith DA, Kitteringham NR and Park BK (1995) An investigation of the interaction between halofantrine, CYP2D6 and CYP 3A4: Studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 35:369-374.
21. Hanssen-Grant S, Silk KS and Guthrie S (1993) Fluoxetine-pimozide interaction. Am J Psychiatry 150:1751-1752.
22. Harris JW, Rahman A, Kim BR, Guengerich FP and Collins JM (1994) Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035.
23. Heyn HH, White RB and Stevens JC (1996) Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 24:948-954.
24. Horrigan JP and Barnhill LJ (1994) Paroxetine-pimozide interaction. J Am Acad Child Adolesc Psychiatry 33:1060-1061.
25. Inaba T, Jurima M, Mahon WA and Kalow W (1985) In vitro inhibition studies of two isoenzymes of human liver cytochrome P-450: Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 13:443-448.
26. Kerbuach T, Desta Z, Soukhova NV, Thacker D and Flockhart DA (1997) Sensitive assay for pimozide in human plasma using high-performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies. J Chromatogr 694:163-168.
27. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS and Gallahan AM (1995) The emerging role of cytochrome P450 in psychopharmacology. J Clin Psychopharmacol 15:387-398.
28. Ko J-W, Soukhova N, Thacker D, Chen P and Flockhart DA (1997) Evaluation of omeprazole and Lanaoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 26:853-862.
29. Krthenbühl S, Sauter B, Kupferschmidt H, Krause M, Wyss P and Meier PJ (1995) Case report: reversible QT prolongation with torsade de pointes in a patient with ptoozide intoxication. Am J Med Sci 309:315-316.
30. May DG (1994) Genetic differences in drug disposition. J Clin Pharmacol 34:881-897.
31. McCreadie RG, Mackie M, Wiles DH, Jorgensen A, Hansen V and Menzies C (1984) Within-individual vahation in steady state plasma levels of different neuroleptics and prolactin. Br J Psychiatry 144:625-629.
32. Newton DJ, Wang RW and Lu AYH (1995) Cytochrome P450 inhibitors: Evaluation of ipecificities in the in vitro metabolism of therapeutic agents by human liver microsomes Drug Metab Dispos 23:154-158.
33. Nahata M (1996) Drug interaction with azithromycin and the macrolides: An overview. J Antimicrob Chemother 37: suppl. C,133-142.
34. Opler LA and Feinberg SS (1991) The role of pimozide in clinical psychiatry: A review. J Clin Psychiatry 52:221-223.
35. Ortiz de Montellano PR, Mathews JM, Kunze KL, Miwa GT and Lu Ayh (1981) Selective inactivation of cytochrome P450 isoenzymes by suicide substrate. Arch Biochem Biophys 210:717-728.
36. Parsons WD and Neims AH (1978) Effect of smoking on caffeine clearance. Clin Pharmacol Ther 24:40-45.
37. Peter R, Bocker R, Beaune PH, Iwaski M, Guengerich FP and Xang CS (1990) Hydroxylation of chloroxazone as a specific probe of cytochrome P450 IIE1. Chem Res Toxicol 3:566-573.
38. Pinder RM, Brogden RN, Sawyer PR, Speigt TM, Spencer R and Avery GS (1976) Pimozide: A review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 12:1-40.
39. Pollard HB, Menard R, Brabdt HA, Pazolzs CJ, Creutz CE and Ramu A (1978) Application of Bradford's assay to adrenal gland subcellular fractions. Anal Biochem 86:761-763.
40. Helling MV, Aoyama T, Gonzalez FJ and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-447
41. 14C] dextromethorphan, Anal Biochem 219:309-320.
42. Sallee FR, Pollock BG, Stiller RL, Stull S, Everett G and Perel JM (1987) Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. J Clin Pharmacol 27:776-781.
43. Sallee FR, Nesbitt L, Jackson C, Sine L and Sethuraman G (1997) Relative efficacy of haloperidol and pimozide in children and adolescents with Tourett's disorder. Am J Psychiatry 154:1057-1062.
44. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, Torre R and Davies DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651-663.
45. Shapiro E, Shapiro AK and Fulop G, Hubbard M, Mandeli J, Nordlie J, Phillips RA (1989) Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome, Arch Gen Psychiatry 79:1032-1039.
46. Shimada T, Yamazaki H, Mimaru M, Inui Y and Guengerich FP (1994) Interindividual variation in human liver cytochrome P450 enzyme involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microaomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
47. Soudijn W and Wijngaarden I (1969) The metabolism and excretion of the neuroleptic pimozide by the Wistar rat. Life Sci 8:291-295.
48. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gslboin HV and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
49. Tueth MJ and Cheong JA (1993) Clinical uses of pimozide. South Med J 86:344-349.
50. Ueng Y-F, Kuwabara T, Chun Y-J and Guergerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
51. VandenBranden M, Ring BJ, Binkley SN and Wrighton SA (1996) Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 6:81-91.
52. Woosley RL, Chen Y, Frieman J and Gillis RA (1993) Mechanism of cardiotoxicity of terfenadine. JAMA 269:403-409.
53. Wrighton SA, Stevens JC, Becker GW and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation, Arch Biochem Biophys 306:240-245
54. Wu D, Otton SV, Sproul BA, Busto U, Inaba T, Kalow W and Sellers EM (1993) Inhibition of cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 35:30-34